|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 216-221.
Prepublished online as a Blood First Edition Paper on August 21, 2003; DOI 10.1182/blood-2003-05-1401.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index
Chor-Sang Chim,
Shing-Yan Ma,
Wing-Yan Au,
Carolyn Choy,
Albert K. W. Lie,
Raymond Liang,
Chun-Chung Yau, and
Yok-Lam Kwong
From the Departments of Medicine, Pathology, and Radiation Oncology, University of Hong Kong, Queen Mary Hospital, Hong Kong.
Nasal natural killer (NK) cell lymphoma is rare, so that its optimal therapy, long-term outcome, and prognostic factors are unclear. Data on 52 men and 15 women with well-characterized nasal NK cell lymphomas were analyzed retrospectively to define the impact of primary therapy on remission and long-term outcome and the validity of the International Prognostic Index (IPI). Most (84%) had stage I/II disease with an IPI score of 1 or less (52%). Seven patients received radiotherapy only; 47 patients received anthracycline-containing chemotherapy plus consolidation radiotherapy; and 12 patients received nonanthracycline-containing chemotherapy plus radiotherapy. The overall complete remission (CR) rate was 64.2%; the 20-year overall survival (OS) and disease-free survival (DFS) rates were 37.1% and 33.5%, respectively. Front-line radiotherapy was apparently better than chemotherapy for CR (100% versus 59%, P = .04) and OS (83.3% versus 32.0%, P = .03). Relapses occurred in 4 radiotherapy-treated (all local) and 14 chemotherapy-treated patients (9 local, 4 systemic). Among these, 5 late relapses (4 local, 1 systemic) occurred at 170 months (range, 92-348 months) from CR. The IPI score was of prognostic significance for the whole group (IPI  1 superior to IPI  2 for 20-year OS: 57.4% versus 27.6%, P = 0.012), as well as for patients treated with chemotherapy/radiotherapy (IPI 1 superior to IPI 2 for CR: 76.7% versus 35.7%, P = .017; and 10-year OS: 63.8% versus 26.8%, P = .003).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Suzuki, J. Suzumiya, M. Yamaguchi, S. Nakamura, J. Kameoka, H. Kojima, M. Abe, T. Kinoshita, T. Yoshino, K. Iwatsuki, et al.
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
Ann. Onc.,
October 22, 2009;
(2009)
mdp418v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, J. Suzumiya, and K. Oshimi
Differences between nasal and extranasal NK/T-cell lymphoma
Blood,
June 11, 2009;
113(24):
6260 - 6261.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-y. Au, D. D. Weisenburger, T. Intragumtornchai, S. Nakamura, W.-S. Kim, I. Sng, J. Vose, J. O. Armitage, R. Liang, and for the International Peripheral T-Cell Lymphoma P
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Blood,
April 23, 2009;
113(17):
3931 - 3937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Li, Q.-F. Liu, H. Fang, S.-N. Qi, H. Wang, W.-H. Wang, Y.-W. Song, J. Lu, J. Jin, S.-L. Wang, et al.
Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma
Clin. Cancer Res.,
April 15, 2009;
15(8):
2905 - 2912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-S. Kim, D.-W. Kim, S.-A. Im, C. W. Kim, T.-Y. Kim, S.-S. Yoon, D. S. Heo, Y.-J. Bang, S. Park, B. K. Kim, et al.
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
Ann. Onc.,
January 1, 2009;
20(1):
121 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jaccard, B. Petit, S. Girault, F. Suarez, R. Gressin, J.-M. Zini, V. Coiteux, C. Larroche, A. Devidas, C. Thieblemont, et al.
L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature
Ann. Onc.,
January 1, 2009;
20(1):
110 - 116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Sandlund
Clinical Features and Treatment Approaches for the Uncommon Non-Hodgkin Lymphoma Subtypes in Children
ASCO Educational Book,
January 1, 2009;
2009(1):
598 - 603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Shen, W.-Y. Au, K.-Y. Wong, N. Shimizu, J. Tsuchiyama, Y.-L. Kwong, R. H. Liang, and G. Srivastava
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells
Mol. Cancer Ther.,
December 1, 2008;
7(12):
3807 - 3815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Ann. Onc.,
December 1, 2008;
19(12):
2079 - 2083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Li, H. Fang, Q.-F. Liu, J. Lu, S.-N. Qi, H. Wang, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, et al.
Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring
Blood,
October 15, 2008;
112(8):
3057 - 3064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Kim, S. -Y. Lee, Y. K. Jeon, B. -Y. Ryoo, G. J. Cho, Y. S. Hong, H. J. Kim, S.-Y. Kim, C. S. Kim, S. Kim, et al.
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
Ann. Onc.,
August 1, 2008;
19(8):
1477 - 1484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage
Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas
Hematology,
January 1, 2008;
2008(1):
280 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kim, B. Kim, C. Choi, J Choi, I Kim, Y-H Lee, and J. Kim
Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type
Ann. Onc.,
August 1, 2007;
18(8):
1382 - 1387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al.
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood,
March 1, 2007;
109(5):
2183 - 2189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Li, B. Yao, and J. Jin
In Reply:
J. Clin. Oncol.,
June 10, 2006;
24(17):
2685 - 2686.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, et al.
NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey
Ann. Onc.,
May 1, 2006;
17(5):
794 - 800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al.
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
J. Clin. Oncol.,
February 1, 2006;
24(4):
612 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al.
Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma
J. Clin. Oncol.,
January 1, 2006;
24(1):
181 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-S. Chim, Y.-L. Kwong, A. K.-W. Lie, S.-K. Ma, C.-C. Chan, L.-G. Wong, B. C. San Kho, H.-K. Lee, J. P.-Y. Sim, C.-H. Chan, et al.
Long-term Outcome of 231 Patients With Essential Thrombocythemia: Prognostic Factors for Thrombosis, Bleeding, Myelofibrosis, and Leukemia
Arch Intern Med,
December 12, 2005;
165(22):
2651 - 2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al.
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type
Blood,
December 1, 2005;
106(12):
3785 - 3790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C-S Chim, E S K Ma, F Loong, and Y-L Kwong
Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement
J. Clin. Pathol.,
April 1, 2005;
58(4):
443 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-Y. Au, S.-Y. Ma, C.-S. Chim, C. Choy, F. Loong, A. K. W. Lie, C. C. K. Lam, A. Y. H. Leung, E. Tse, C.-C. Yau, et al.
Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years
Ann. Onc.,
February 1, 2005;
16(2):
206 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology,
January 1, 2005;
2005(1):
267 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
Ann. Onc.,
October 1, 2004;
15(10):
1467 - 1475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Y. You, K.-H. Chi, M.-H. Yang, C.-C. Chen, C.-H. Ho, W.-K. Chau, H.-C. Hsu, J.-P. Gau, C.-H. Tzeng, J.-H. Liu, et al.
Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan
Ann. Onc.,
April 1, 2004;
15(4):
618 - 625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
